CTI BIOPHARMA CORP. CTIC Cash Flow

Cti biopharma corp. (CTIC)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Operating activities
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
-41,395	-40,023	-30,992	-35,763	-36,131	-29,352	-44,467	-41,648	-24,931	-40,831	-33,122	-50,484	-75,879	-52,953	-72,408	-76,143	-88,887	-120,763	-136,661	-99,205	-93,918	-94,229	-42,345	-62,389	-53,130	-43,550	-72,234	-71,796	-103,774	-101,687	0	0	0	-	-	-	-
Adjustments to reconcile net loss to net cash used in operating activities:
Baxalta milestone revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	32,000	32,000	32,000	32,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Equity-based compensation
5,100	5,200	5,407	6,642	6,364	6,400	6,301	5,128	5,237	5,700	6,402	10,115	11,297	13,324	13,056	13,876	14,318	14,828	16,171	14,120	16,703	20,196	19,764	17,855	14,467	9,066	8,178	7,266	8,383	7,938	8,781	8,545	6,456	5,017	0	0	0
Depreciation and amortization
539	546	564	574	588	600	607	620	659	700	736	771	792	831	869	920	961	990	982	996	1,001	1,100	1,268	1,399	1,549	1,600	1,808	2,077	2,236	2,346	2,408	2,447	2,488	2,411	0	0	0
Provision for Italian VAT receivables and deposit
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Write-off of deferred financing costs
-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for bad debt
-	-	-	-	-	-	-	-	-	-	-	-	-	1,735	1,560	345	321	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other-than-temporary impairment on available-for-sale securities
-	-	-	-	-	-	-	-	-	-	-	-	-	520	519	519	519	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Noncash interest expense
-	-	-	-	-	525	444	352	259	163	150	150	151	214	216	218	311	390	533	677	731	729	711	689	668	513	0	0	0	-	-	-	-	546	0	0	0
Noncash rent benefit
-	-	-	-	-	1,424	1,459	1,372	1,064	648	511	498	483	467	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	886	699	918	861	0	0	0	0	-	-	-	-	-	-	-	-
Noncontrolling interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Other
62	-191	-569	-386	-1,009	-794	0	0	0	-	-	-	-	-	-	-	-	-	-	624	612	20	-537	-613	-613	-365	-345	-547	-233	-5	1,911	2,187	1,806	1,958	0	0	0
Changes in operating assets and liabilities:
Receivables from license and development services arrangements
0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts receivable
-	-	-	-	-	-	-	-	-	-	-	-400	-596	156	70	40	-339	-1,555	-306	627	1,176	1,980	735	-183	-297	227	0	0	0	-	-	-	-	-	-	-	-
Receivables from collaborative arrangements
-	-	-	-	-	-	-	-	-	-	-	-4,626	1,816	9,476	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Inventory
-	-	-	-	-	-	-	-	-	-1,120	-1,275	-438	-547	-567	573	378	459	402	-700	-528	-380	-305	1,144	1,491	2,454	3,254	0	0	0	-	-	-	-	-	-	-	-
Prepaid expenses and other assets
-1,186	-1,120	597	29	-708	163	-14	181	163	-326	-596	-1,075	-4,203	-1,609	-2,261	-2,126	1,467	402	1,457	1,219	754	-46	368	572	-486	-4,530	-2,789	-4,329	-302	3,759	-412	2,665	67	-567	0	0	0
Accounts payable, accrued expenses and other liabilities
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other assets
-	-	-	-	-	-	150	84	-57	-63	-110	-139	-446	-355	-379	87	469	-826	-1,168	-1,208	-1,367	356	742	567	962	846	-1,512	-1,514	-1,305	-1,495	722	518	5	2,452	0	0	0
Accounts payable
-	-	-	-	-	-	41	-305	-9,784	-4,730	-11,630	-10,035	-5,510	-3,025	590	3,118	7,157	4,368	7,189	5,084	6,195	1,454	-3,627	-4,540	-5,817	-5,774	153	651	3,030	3,123	2,232	1,908	820	-310	0	0	0
Accrued expenses
-	-	-	-	-	-	738	-7,551	-6,731	-11,096	-7,992	4,734	2,015	2,620	5,566	-716	4,022	2,426	1,640	5,718	5,321	10,250	7,740	1,990	-285	-834	-1,458	1,221	1,683	-885	-1,349	-623	-1,293	-211	0	0	0
Deferred revenue
-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	681	-787	-1,071	-1,160	-1,027	-812	-918	-990	-21	-102	-31	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Other liabilities
-	-	-	-	-	-	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-25	40	524	4,843	4,528	0	0	0	-	-	-	0
Total adjustments
-	-	-	-	-	-	-	-	-	-	-	14,648	13,559	-23,727	-11,785	-19,018	-5,373	25,560	67,389	49,136	51,154	54,679	9,309	18,746	11,859	7,720	9,022	11,621	44,642	38,911	40,774	38,627	5,566	2,161	0	0	0
Net cash used in operating activities
-34,808	-27,822	-28,985	-35,460	-40,857	-39,824	-37,677	-46,359	-33,019	-39,296	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-51,425	-54,988	-54,848	-60,458	0	0	0
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-94,260	-	-69,272	-50,069	-42,764	-39,550	-33,036	-43,643	-41,271	-35,830	0	0	0	-	-	-	-	-	-	-	-
Investing activities
Purchases of property and equipment
-	-	-	-	-	33	82	82	82	49	0	29	108	137	184	162	83	78	106	299	322	333	542	360	674	1,657	2,344	3,263	3,741	2,937	2,695	2,565	2,590	2,703	0	0	0
Proceeds from maturities of short-term investments
32,650	39,150	37,510	27,510	20,610	11,610	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sales of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	123	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by investing activities
21,632	28,132	16,348	9,376	-21,457	-30,490	-27,994	-27,525	-71	-38	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-20,455	-19,616	-2,559	-2,672	0	0	0
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-83	-	-314	-507	-530	-541	-542	-289	-597	-1,534	0	0	0	-	-	-	-	-	-	-	-
Financing activities
Proceeds from rights offering, net of issuance costs
59,280	0	0	0	-418	64,170	64,170	64,170	64,588	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments of issuance costs from Silicon Valley Bank debt, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from debt, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Principal payments on debt
5,333	5,333	4,444	3,111	1,777	444	14,964	15,639	17,614	19,548	6,458	7,597	7,386	5,452	3,578	1,764	2,362	4,659	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments of Stock Issuance Costs
230	275	213	218	311	268	0	0	0	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of tax withholding obligations related to restricted stock awards
-	-	-	-	-	21	0	0	0	-	-	-	-	355	335	364	190	604	591	614	600	178	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for repurchase of shares in connection with taxes on restricted stock vesting
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Other
-	-	-	-	-	-	-	-	-	-	-83	-69	-7	30	103	163	377	165	302	243	95	280	390	341	101	3	-221	-244	-253	-214	-720	-6,487	-507	-424	0	0	0
Net cash used in financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	154,805	-	84,392	68,650	33,195	36,026	34,618	49,399	49,128	58,972	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by (used in) financing activities
53,718	-5,607	-4,656	-3,314	-2,472	63,491	65,089	64,030	105,536	38,979	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	40,374	48,555	40,035	87,004	0	0	0
Effect of exchange rate changes on cash and cash equivalents
-	-	-	-	-	-	-	-	0	-	0	0	0	-	0	0	-216	-	1,639	3,606	3,893	3,359	1,694	-851	-973	-405	-462	-105	584	-355	583	1,917	938	529	0	0	0
Net increase in cash, cash equivalents and restricted cash
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effect of exchange rate changes on cash and cash equivalents
14	2	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase in cash and cash equivalents
40,556	-5,295	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase in cash and cash equivalents
-	-	-	-	-	-	-	-	0	-	-	-	-	-	0	0	60,246	-	16,445	21,680	-6,206	-706	2,734	4,616	6,287	21,203	12,887	13,813	16,934	3,384	-30,923	-24,132	-16,434	24,403	0	0	0
Supplemental disclosure of cash flow information
Cash paid during the period for interest
922	1,044	1,145	1,199	1,214	1,197	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid during the period for interest
-	-	-	-	-	-	-	-	-	-	-	2,332	2,525	4,446	4,408	4,281	4,015	2,067	2,018	1,943	1,979	1,894	1,698	1,542	1,367	933	624	311	16	16	330	331	1,028	1,025	0	0	0
Cash paid during the period for taxes
-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	0	0	-	0	0	0	0	0	0	0
Supplemental disclosure of noncash financing and investing activities
Right-of-use assets obtained in exchange for operating lease liabilities
-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Debt issuance costs included in accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Exchange of common stock and preferred stock for preferred stock
-	-	-	-	-	-	65,659	65,659	65,659	41,579	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common stock issuance costs included in accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of common stock upon exercise or exchange of common stock purchase warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,877	0	0	0	-	-	-	-	-	-	-	-	17,485	0	0	0
Baxalta milestone advance - earned in lieu of repayment
-	-	-	-	-	-	-	-	-	-	-	-	-	32,000	32,000	32,000	32,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Redemption of Series 8 and 10 preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	36,638	0	0	0